Skip to main content

Advertisement

SpringerLink
Log in

Abnormal APP processing in platelets of patients with Alzheimer’s disease: correlations with membrane fluidity and cognitive decline

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Rationale

Previous studies have implicated platelet amyloid precursor protein (APP) as a candidate biomarker for Alzheimer’s disease (AD). Platelets contain more than 95% of the circulating APP and enclose the enzymatic machinery for the APP metabolism yielding both soluble APP and amyloid-β peptides.

Objectives

The objective of this study is to compare the ratio of 130- to 110-kDa fragments of APP in platelets from patients with AD, mild cognitive impairment (MCI), and elderly controls.

Materials and methods

After subjects were grouped according to diagnosis, APP ratio in platelets was evaluated by means of Western blot analysis.

Results

The APP ratio was significantly lower in AD patients (1.01 ± 0.21) as compared to controls (1.24 ± 0.21, p = 0.001) and MCI patients (1.18 ± 0.21, p = 0.027), but no significant differences were found between MCI and controls (p = 0.904). In addition, we found positive correlations between the APP ratio and 1,6-diphenyl-1,3,5-hexatriene anisotropy (r = 0.3, p = 0.01), as well as with certain parameters of cognitive decline, namely, the mini-mental state examination score (r = 0.33, p = 0.003), the total Cambridge cognitive test (CAMCOG) score (r = 0.37, p = 0.001), and the score on the memory subscale of the CAMCOG (r = 0.38, p = 0.001).

Conclusions

The pattern of platelet APP fragments was altered in patients with AD but not in patients with MCI. The alteration of APP fragments was correlated with membrane fluidity and the cognitive decline.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  • American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington

    Google Scholar 

  • Army Individual Test Battery (1944) Manual of directions and scoring war department, Adjunt General’s Office Trail, Washington

  • Baskin F, Rosenberg RN, Iyer L, Hynan L, Cullum CM (2000) Platelet APP isoform ratios correlated with declining cognition in AD. Neurology 54:1907–1909

    PubMed  CAS  Google Scholar 

  • Blessed G, Tomlinson BE, Roth M (1968) The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 114:797–811

    PubMed  CAS  Google Scholar 

  • Daly IVJ, Lahiri DK, Justus DE, Kotwal GJ (1998) Detection of the membrane-retained carboxy-terminal tail containing polypeptides of the amyloid precursor protein in tissue from Alzheimer’s disease brain. Life Sci 63:2121–2131

    Article  PubMed  CAS  Google Scholar 

  • Davies TA, Long HJ, Sgro K, Rathbun WH, Mcmenamin ME, Seetoo K, Tibbles H, Billingslea AM, Fine RE, Fishman JB, Levesque CA, Smith SJ, Wells JM, Simons ER (1997) Activated Alzheimer disease platelets retain more beta amyloid precursor protein. Neurobiol Aging 18:147–153

    Article  PubMed  CAS  Google Scholar 

  • Di Luca M, Pastorino L, Cattabeni F, Zanardi R, Scarone S, Racagni G, Smeraldi E, Perez J (1996) Abnormal pattern of platelet APP isoforms in Alzheimer disease and Down syndrome. Arch Neurol 53:1162–1166

    PubMed  Google Scholar 

  • Di Luca M, Pastorino L, Bianchetti A, Perez J, Viagnolo LA, Lenzi GL, Trabucchi M, Cattebeni F, Padovani A (1998) Differential level of platelet amyloid β precursor protein isoforms—an early marker for Alzheimer disease. Arch Neurol 55:1195–1200

    Article  PubMed  Google Scholar 

  • Di Luca M, Colciaghi F, Pastorino L, Borroni B, Padovani A, Cattabeni F (2000) Platelets as a peripheral district were to study pathogenetic mechanisms of Alzheimer disease: the case of amyloid precursor protein. Eur J Pharmacol 405:277–283

    Article  PubMed  Google Scholar 

  • Eckert GP, Cairns NJ, Maras A, Gattaz WF, Muller WE (2000) Cholesterol modulates the membrane-disordering effects of beta-amyloid peptides in the hippocampus: specific changes in Alzheimer’s disease. Dement Geriatr Cogn Disord 11(4):181–186

    Article  PubMed  CAS  Google Scholar 

  • Erzigkeit H (1991) The development of the SKT project. In: Hindmarch I, Hippius H, Wilcock GK (eds) Dementia: molecules, methods and measures. Wiley, Chichester, England, pp 101–108

    Google Scholar 

  • Fernandes MAS, Proença MT, Nogueira AJA, Oliveira LMV, Santiago B, Santana I, Oliveira CR (1999) Effects of apolipoprotein E genotype on blood lipid composition and membrane platelet fluidity in Alzheimer’s disease. Biochim Biophys Acta 1454:89–96

    PubMed  CAS  Google Scholar 

  • Flaks MK, Yassuda MS, Regina ACB, Cid AG, Camargo CHP, Gattaz WF, Forlenza OV (2006) The short test (SKT)—a transcultural test for early detection and discrimination of dementia: a preliminary study in Brazil. Int Psychogeriatr 18:121–133

    Article  PubMed  Google Scholar 

  • Folstein MF, Folstein SE, Mchugh PR (1975) Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198

    Article  PubMed  CAS  Google Scholar 

  • Fuld P (1980) Guaranteed stimulus processing in the evaluation of memory and learning. Cortex 16:255–271

    PubMed  CAS  Google Scholar 

  • Haass C (2004) Take five-Bace and the γ-secretase quartet conduct Alzheimer’s amyloid β-peptide generation. EMBO J 23:483–488

    Article  PubMed  CAS  Google Scholar 

  • Hachinski VC, Iliff ID, Zihkla E, Du Boulay GH, McAllister VL, Marshall J, Russel RW, Symon L (1975) Cerebral blood flow in dementia. Arch Neurol 32:632–637

    PubMed  CAS  Google Scholar 

  • Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62

    Article  PubMed  CAS  Google Scholar 

  • Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Möller H-J, Blennow K, Buerger K (2004) Value of CSF β-amyloid1–42 and tau as predictors of Alzheimer’s disease in patients with mild cognitive impairment. Mol Psychiatry 9:705–710

    PubMed  CAS  Google Scholar 

  • Hansson O, Zetterberg H, Buchhave P, Londos L, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5:228–234

    Article  PubMed  CAS  Google Scholar 

  • Jorm AF, Jacomb PA (1989) The informant questionnaire on cognitive decline in the elderly: sociodemographics correlates, reliability, validity and some norms. Psychol Med 19:1015–1022

    Article  PubMed  CAS  Google Scholar 

  • Kukull WA, Hinds TR, Schellenberg GD, Belle Gv, Larson EB (1992) Increased platelet membrane fluidity as a diagnostic marker for Alzheimer’s disease. Neurology 42:607–614

    PubMed  CAS  Google Scholar 

  • Li QX, Whyte S, Tanner JE, Evin G, Beyreuther K, Masters CL (1998) Secretion of Alzheimer’s disease Aβ amyloid peptide by activated human platelets. Lab Invest 78:461–469

    PubMed  CAS  Google Scholar 

  • Maruyama M, Arai H, Sugita M, Tanji H, Higuchi M, Okamura N, Matsui T, Higuchi S, Matsushita S, Yoshida H, Sasaki H (2001) Cerebrospinal fluid amyloid β1–42 levels in the mild cognitive impairment stage of Alzheimer’s disease. Exp Neurol 172:433–439

    Article  PubMed  CAS  Google Scholar 

  • Mc Khann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer disease: report of NINCDS–ADRDA work group under the auspices of Department of Health and Human Service Task Force on Alzheimer disease. Neurology 34:939–944

    CAS  Google Scholar 

  • Müller WE, Kock S, Eckert A, Hartmann H, Scheuer K (1995) β-amyloid peptide decreases membrane fluidity. Brain Res 674:133–136

    Article  PubMed  Google Scholar 

  • Müller WE, Koch S, Scheur K, Rostock A, Bartsch R (1997) Effects of piracetam on membrane fluidity in the aged mouse, rat, and human brain. Biochem Pharmacol 53(2):135–140

    Article  PubMed  Google Scholar 

  • Oliveira R, Schmidt SL (1999) Teste Comportamental de Memória de Rivermead. Cognição, Rio de Janeiro

    Google Scholar 

  • Padovani A, Borroni B, Colciaghi F, Pettenati C, Cottini E, Agosti C, Lenzi GL, Caltagirone C, Trabucchi M, Cattabeni F, Di Luca M (2002) Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer disease. Arch Neurol 59:71–75

    Article  PubMed  Google Scholar 

  • Petersen RC (2005) Mild cognitive impairment: useful or not? Alzheimer’s Dement 1:5–10

    Article  Google Scholar 

  • Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56:303–308

    Article  PubMed  CAS  Google Scholar 

  • Racchi M, Govoni S (2003) The pharmacology of amyloid precursor protein processing. Exp Gerontol 38:145–157

    Article  PubMed  CAS  Google Scholar 

  • Rosenberg RN, Baskin F, Fosmire JA, Risser R, Adams P, Svetlik D, Honig LS, Cullun MC, Weiner MF (1997) Altered amyloid protein processing in platelets of patients with Alzheimer disease. Arch Neurol 54:139–144

    PubMed  CAS  Google Scholar 

  • Roth M, Hopkins B (1953) Psychological test performance in patients over 60. I. Senile psychosis and affective disorders of old age. J Ment Sci 99:439–450

    PubMed  CAS  Google Scholar 

  • Roth M, Tym E, Mountjoy CQ, Huppert FA, Hendrie H, Verma S, Goddard R (1986) CAMDEX: a standardized instrument for the diagnosis of mental disorders in the elderly with special reference to early detection of dementia. Br J Psychiatry 149:698–709

    Article  PubMed  CAS  Google Scholar 

  • Skovronsky DM, Lee VMY, Praticò D (2001) Amyloid precursor protein and amyloid β peptide in human platelet. J Biol Chem 276:17036–17043

    Article  PubMed  CAS  Google Scholar 

  • Sunderland T, Hill Jl, Mellow AM, Lawlor BA, Gundersheimer J, Newhouse PA, Grafman JH (1989) Clock drawing in Alzheimer’s disease. A novel measure of disease severity. J Am Geriatr Soc 37:725–729

    PubMed  CAS  Google Scholar 

  • Tang K, Hynan LS, Baskin F, Rosenberg RN (2006) Platelet amyloid precursor protein processing: a bio-marker for Alzheimer’s disease. J Neurol Sci 240:53–58

    Article  PubMed  CAS  Google Scholar 

  • Wechsler DI (1981) Examiner’s manual: Wechsler adult intelligence scale-revised. Psychological Corporation, New York

    Google Scholar 

  • Wilson B, Cockburn J, Baddeley AD (1985) Rivermead behavioural memory test. Thames Valley, Suffolk

    Google Scholar 

  • Wood WG, Eckert GP, Igbavboa U, Müller WE (2003) Amyloid beta-protein interactions with membranes and cholesterol: causes or casualties of Alzheimer’s disease. Biochimica et Biophysica Acta 1610(2):281–290

    Article  CAS  Google Scholar 

  • Zubenko GS, Malinakova I, Chojnacki B (1987a) Proliferation of internal membranes in platelets from patients with Alzheimer’s disease. J Neuropathol Exp Neurol 46:407–418

    PubMed  CAS  Google Scholar 

  • Zubenko GS, Wusylko M, Cohen BM, Boller F, Teply I (1987b) Family study of platelet membrane fluidity in Alzheimer disease. Science 238:539–542

    Article  PubMed  CAS  Google Scholar 

  • Zubenko GS, Kopp U, Seto T, Firestone LL (1999) Platelet membrane fluidity individuals at risk for Alzheimer’s disease: a comparison of results from fluorescence spectroscopy and electron spin resonance spectroscopy. Psychopharmacology 145:175–180

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The present work was supported by FAPESP, Fundação de Amparo à Pesquisa do Estado de São Paulo (Project 02/13633-7). The authors are grateful to Dr. Breno S. O. Diniz and Carolina A. Torres. The Laboratory of Neurosciences receives financial support from Associação Beneficente Alzira Denise Hertzog da Silva.

Author information

Authors and Affiliations

  1. Laboratory of Neuroscience (LIM 27), Department and Institute of Psychiatry, Faculty of Medicine, University of São Paulo, Rua Doutor Ovídio Pires de Campos, 785, CEP 05403-010, São Paulo, SP, Brazil

    Isis A. Zainaghi, Orestes V. Forlenza & Wagner F. Gattaz

Authors
  1. Isis A. Zainaghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Orestes V. Forlenza
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wagner F. Gattaz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Orestes V. Forlenza.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zainaghi, I.A., Forlenza, O.V. & Gattaz, W.F. Abnormal APP processing in platelets of patients with Alzheimer’s disease: correlations with membrane fluidity and cognitive decline. Psychopharmacology 192, 547–553 (2007). https://doi.org/10.1007/s00213-007-0748-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-007-0748-5

Keywords

Search

Navigation